HOME >> MEDICINE >> NEWS
UCL conference to launch global health institute

Migration, maternal and child health, healthy ageing and the economics of health inequalities and well-being are among the global health topics to be discussed at a conference held at UCL (University College London) on 14th and 15th October to launch the UCL International Institute for Society and Health (IISH).

The IISH conference will include speeches by Professor Anthony Costello, UCL Institute of Child Health, who has spent time working with women's groups in populations in south Asia and Africa to improve maternal & child health and an opening address by the author of the book Status Syndrome, Professor Sir Michael Marmot.

Professor Richard Blundell, Research Director of the Institute of Fiscal Studies, will join Professor Marmot to talk on social inequalities.

Professor Marmot said: "There is no longer one set of diseases for rich countries and another for poor but diseases linked to economic and social conditions that vary within and between countries. The new UCL institute has a scientific agenda and a moral concern to deal with global health problems."

The new Institute will be linked with a WHO Commission on the Social Determinants of Health, and aims to conduct research and develop actions that will improve health in developed and less developed countries. IISH will link research in biotechnology, humanities, medicine and social sciences, to tackle disease and its causes.

Key speeches at the conference:

  • Professor Marmot, UCL Department of Epidemiology, will talk on health inequalities
  • Professor Anthony Costello, UCL Institute of Child Health, will talk on maternal and child health with Professor Cesar Victora, University of Pelotas, Brazil
  • Professor Katherine Homewood, UCL Department of Anthropology, will talk on the cultural dimensions of health inequalities with Professor Veena Das, Krieger-Eisenhower Professor at John Hopkins University
  • Professor James Banks, UCL Department of Ec
    '"/>


Contact: Judith H. Moore
judith.moore@ucl.ac.uk
020-767-97678
University College London
6-Oct-2005


Page: 1 2

Related medicine news :

1. Cedars-Sinai researchers present new endocrine findings at 2 international conferences
2. WFU to host international conference of physicists
3. Sight specialists to shed light on vision loss at UH conference
4. University of Alberta hosts international conference on women in the knowledge economy and society
5. Worlds largest clinical trial into rare bone cancer well underway conference hears
6. Dobbs to give plenary keynote at Drug Information Association conference in Philadelphia, Sept. 26
7. Feinstein Institutes top scientist weighs in on mind-body medicine at conference with Dalai Lama
8. Institute of Medicine advisory: Drug safety news conference September 26
9. Nobel Laureate keynote speaker at conference on nanomedicine, geriatric care, brain injury
10. Yale helps organize conference to identify new treatments for Tourette Syndrome
11. Thousands find connection and inspiration at nations largest autism conference

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCL conference launch global health institute

(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: